Form 8-K

8-K — IMMUNIC, INC.

Accession: 0001193805-26-001196

Filed: 2026-09-09

Period: 2026-09-09

CIK: 0001280776

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — e665768_8k-immunic.htm (Primary)

EX-99.1 (e665768_ex99-1.htm)

GRAPHIC (slide1.jpg)

GRAPHIC (slide2.jpg)

GRAPHIC (slide3.jpg)

GRAPHIC (slide4.jpg)

GRAPHIC (slide5.jpg)

GRAPHIC (slide6.jpg)

GRAPHIC (slide7.jpg)

GRAPHIC (slide8.jpg)

GRAPHIC (slide9.jpg)

GRAPHIC (slide10.jpg)

GRAPHIC (slide11.jpg)

GRAPHIC (slide12.jpg)

GRAPHIC (slide13.jpg)

GRAPHIC (slide14.jpg)

GRAPHIC (slide15.jpg)

GRAPHIC (slide16.jpg)

GRAPHIC (slide17.jpg)

GRAPHIC (slide18.jpg)

GRAPHIC (slide19.jpg)

GRAPHIC (slide20.jpg)

GRAPHIC (slide21.jpg)

GRAPHIC (slide22.jpg)

GRAPHIC (slide23.jpg)

GRAPHIC (slide24.jpg)

GRAPHIC (slide25.jpg)

GRAPHIC (slide26.jpg)

GRAPHIC (slide27.jpg)

GRAPHIC (slide28.jpg)

GRAPHIC (slide29.jpg)

GRAPHIC (slide30.jpg)

GRAPHIC (slide31.jpg)

GRAPHIC (slide32.jpg)

GRAPHIC (slide33.jpg)

GRAPHIC (slide34.jpg)

GRAPHIC (slide35.jpg)

GRAPHIC (slide36.jpg)

GRAPHIC (slide37.jpg)

GRAPHIC (slide38.jpg)

GRAPHIC (slide39.jpg)

GRAPHIC (slide40.jpg)

GRAPHIC (slide41.jpg)

GRAPHIC (slide42.jpg)

GRAPHIC (slide43.jpg)

GRAPHIC (slide44.jpg)

GRAPHIC (slide45.jpg)

GRAPHIC (slide46.jpg)

GRAPHIC (slide47.jpg)

GRAPHIC (slide48.jpg)

GRAPHIC (slide49.jpg)

GRAPHIC (slide50.jpg)

GRAPHIC (slide51.jpg)

GRAPHIC (slide52.jpg)

GRAPHIC (slide53.jpg)

GRAPHIC (slide54.jpg)

GRAPHIC (slide55.jpg)

GRAPHIC (slide56.jpg)

GRAPHIC (slide57.jpg)

GRAPHIC (slide58.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: e665768_8k-immunic.htm · Sequence: 1

false

0001280776

2026-09-09

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

September 9, 2026

IMMUNIC, INC.

(Exact name of registrant as specified in its

charter)

Delaware

001-36201

56-2358443

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

1200 Avenue of the Americas, Suite 200

New York, NY 10036

USA

(Address of principal executive offices)

Registrant’s telephone number, including

area code: (332) 255-9818

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of exchange on which registered

Common Stock, par value $0.0001

IMUX

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§ 240.12b2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. Yes ☐ No ☐

Item 7.01. Regulation FD Disclosure

On September 9, 2026, Immunic, Inc. (the “Company”

or “Immunic”) is hosting a Relapsing Multiple Sclerosis (RMS) Research and

Development Day webinar (the “RMS R&D Day”). The RMS R&D Day will

take place on Wednesday, September 9, 2026, from 11:00 a.m. to 12:30 p.m. ET via video conference. The Company intends to use a presentation

during the RMS R&D Day (the “Presentation”) which is attached as Exhibit

99.1 to this Current Report on Form 8-K, and is incorporated herein by reference.

The information in Item 7.01 of this Current Report

on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for the purposes of Section 18 of the Securities

Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it

be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be

expressly set forth therein.

Cautionary Note Regarding Forward-Looking

Statements

Certain statements in this Current Report on Form

8-K and the Presentation are “forward-looking statements” that involve substantial risks and uncertainties for purposes of

the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical

facts, included in this Current Report on Form 8-K, and the Presentation regarding strategy, future operations, future financial position,

future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials,

prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited

to, statements relating to Immunic's development programs and the targeted diseases; the potential for vidofludimus calcium to safely

and effectively target diseases; preclinical and clinical data for vidofludimus calcium; the feasibility of advancing vidofludimus calcium

to a confirmatory phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials, anticipated

clinical milestones and regulatory approvals; the nature, strategy and focus of the company and further updates with respect thereto;

the development and commercial potential of any product candidates of the company; Immunic’s continued listing on The Nasdaq Capital

Market; and expectations regarding the capitalization, resources and ownership structure of the company and its executive and board structure.

Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking

statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s

current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those

projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs

and macroeconomics trends, impacts of the Ukraine - Russia conflict and the conflict in the Middle East on planned and ongoing clinical

trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future

liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational

requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial

results, any changes to the size of the target markets for the company’s products or product candidates, the protection and market

exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process

and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other

factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal

year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company’s subsequent filings with the SEC. Copies

of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this Current Report

on Form 8-K and the Presentation speaks only as of the date of this Current Report on Form 8-K, and the Presentation. Immunic disclaims

any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which

they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents

of this Current Report on Form 8-K and the Presentation.

Item 9.01. Financial Statements and Exhibits.

Exhibit

Description

99.1

Presentation, dated September 9, 2026

104

Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,

as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Dated: September 9, 2026

Immunic, Inc.

By:

/s/ Erik Lundgren

Erik Lundgren

Chief Executive Officer

EX-99.1

Filename: e665768_ex99-1.htm · Sequence: 2

GRAPHIC

Filename: slide1.jpg · Sequence: 6

Binary file (79580 bytes)

Download slide1.jpg

GRAPHIC

Filename: slide2.jpg · Sequence: 7

Binary file (349636 bytes)

Download slide2.jpg

GRAPHIC

Filename: slide3.jpg · Sequence: 8

Binary file (132517 bytes)

Download slide3.jpg

GRAPHIC

Filename: slide4.jpg · Sequence: 9

Binary file (173398 bytes)

Download slide4.jpg

GRAPHIC

Filename: slide5.jpg · Sequence: 10

Binary file (41629 bytes)

Download slide5.jpg

GRAPHIC

Filename: slide6.jpg · Sequence: 11

Binary file (102906 bytes)

Download slide6.jpg

GRAPHIC

Filename: slide7.jpg · Sequence: 12

Binary file (164591 bytes)

Download slide7.jpg

GRAPHIC

Filename: slide8.jpg · Sequence: 13

Binary file (159695 bytes)

Download slide8.jpg

GRAPHIC

Filename: slide9.jpg · Sequence: 14

Binary file (54387 bytes)

Download slide9.jpg

GRAPHIC

Filename: slide10.jpg · Sequence: 15

Binary file (76366 bytes)

Download slide10.jpg

GRAPHIC

Filename: slide11.jpg · Sequence: 16

Binary file (130187 bytes)

Download slide11.jpg

GRAPHIC

Filename: slide12.jpg · Sequence: 17

Binary file (134548 bytes)

Download slide12.jpg

GRAPHIC

Filename: slide13.jpg · Sequence: 18

Binary file (147462 bytes)

Download slide13.jpg

GRAPHIC

Filename: slide14.jpg · Sequence: 19

Binary file (123895 bytes)

Download slide14.jpg

GRAPHIC

Filename: slide15.jpg · Sequence: 20

Binary file (129408 bytes)

Download slide15.jpg

GRAPHIC

Filename: slide16.jpg · Sequence: 21

Binary file (135433 bytes)

Download slide16.jpg

GRAPHIC

Filename: slide17.jpg · Sequence: 22

Binary file (125588 bytes)

Download slide17.jpg

GRAPHIC

Filename: slide18.jpg · Sequence: 23

Binary file (126102 bytes)

Download slide18.jpg

GRAPHIC

Filename: slide19.jpg · Sequence: 24

Binary file (102568 bytes)

Download slide19.jpg

GRAPHIC

Filename: slide20.jpg · Sequence: 25

Binary file (133422 bytes)

Download slide20.jpg

GRAPHIC

Filename: slide21.jpg · Sequence: 26

Binary file (106059 bytes)

Download slide21.jpg

GRAPHIC

Filename: slide22.jpg · Sequence: 27

Binary file (139965 bytes)

Download slide22.jpg

GRAPHIC

Filename: slide23.jpg · Sequence: 28

Binary file (104996 bytes)

Download slide23.jpg

GRAPHIC

Filename: slide24.jpg · Sequence: 29

Binary file (107722 bytes)

Download slide24.jpg

GRAPHIC

Filename: slide25.jpg · Sequence: 30

Binary file (65887 bytes)

Download slide25.jpg

GRAPHIC

Filename: slide26.jpg · Sequence: 31

Binary file (230901 bytes)

Download slide26.jpg

GRAPHIC

Filename: slide27.jpg · Sequence: 32

Binary file (183245 bytes)

Download slide27.jpg

GRAPHIC

Filename: slide28.jpg · Sequence: 33

Binary file (194010 bytes)

Download slide28.jpg

GRAPHIC

Filename: slide29.jpg · Sequence: 34

Binary file (172700 bytes)

Download slide29.jpg

GRAPHIC

Filename: slide30.jpg · Sequence: 35

Binary file (115330 bytes)

Download slide30.jpg

GRAPHIC

Filename: slide31.jpg · Sequence: 36

Binary file (175495 bytes)

Download slide31.jpg

GRAPHIC

Filename: slide32.jpg · Sequence: 37

Binary file (140715 bytes)

Download slide32.jpg

GRAPHIC

Filename: slide33.jpg · Sequence: 38

Binary file (226198 bytes)

Download slide33.jpg

GRAPHIC

Filename: slide34.jpg · Sequence: 39

Binary file (163429 bytes)

Download slide34.jpg

GRAPHIC

Filename: slide35.jpg · Sequence: 40

Binary file (142824 bytes)

Download slide35.jpg

GRAPHIC

Filename: slide36.jpg · Sequence: 41

Binary file (185855 bytes)

Download slide36.jpg

GRAPHIC

Filename: slide37.jpg · Sequence: 42

Binary file (117643 bytes)

Download slide37.jpg

GRAPHIC

Filename: slide38.jpg · Sequence: 43

Binary file (55394 bytes)

Download slide38.jpg

GRAPHIC

Filename: slide39.jpg · Sequence: 44

Binary file (67817 bytes)

Download slide39.jpg

GRAPHIC

Filename: slide40.jpg · Sequence: 45

Binary file (183993 bytes)

Download slide40.jpg

GRAPHIC

Filename: slide41.jpg · Sequence: 46

Binary file (101374 bytes)

Download slide41.jpg

GRAPHIC

Filename: slide42.jpg · Sequence: 47

Binary file (172842 bytes)

Download slide42.jpg

GRAPHIC

Filename: slide43.jpg · Sequence: 48

Binary file (159815 bytes)

Download slide43.jpg

GRAPHIC

Filename: slide44.jpg · Sequence: 49

Binary file (139038 bytes)

Download slide44.jpg

GRAPHIC

Filename: slide45.jpg · Sequence: 50

Binary file (92923 bytes)

Download slide45.jpg

GRAPHIC

Filename: slide46.jpg · Sequence: 51

Binary file (189072 bytes)

Download slide46.jpg

GRAPHIC

Filename: slide47.jpg · Sequence: 52

Binary file (202640 bytes)

Download slide47.jpg

GRAPHIC

Filename: slide48.jpg · Sequence: 53

Binary file (180050 bytes)

Download slide48.jpg

GRAPHIC

Filename: slide49.jpg · Sequence: 54

Binary file (195522 bytes)

Download slide49.jpg

GRAPHIC

Filename: slide50.jpg · Sequence: 55

Binary file (207220 bytes)

Download slide50.jpg

GRAPHIC

Filename: slide51.jpg · Sequence: 56

Binary file (220749 bytes)

Download slide51.jpg

GRAPHIC

Filename: slide52.jpg · Sequence: 57

Binary file (56344 bytes)

Download slide52.jpg

GRAPHIC

Filename: slide53.jpg · Sequence: 58

Binary file (217325 bytes)

Download slide53.jpg

GRAPHIC

Filename: slide54.jpg · Sequence: 59

Binary file (85206 bytes)

Download slide54.jpg

GRAPHIC

Filename: slide55.jpg · Sequence: 60

Binary file (191329 bytes)

Download slide55.jpg

GRAPHIC

Filename: slide56.jpg · Sequence: 61

Binary file (64209 bytes)

Download slide56.jpg

GRAPHIC

Filename: slide57.jpg · Sequence: 62

Binary file (33396 bytes)

Download slide57.jpg

GRAPHIC

Filename: slide58.jpg · Sequence: 63

Binary file (159423 bytes)

Download slide58.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 65

v3.26.1

Cover

Sep. 09, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 09, 2026

Entity File Number

001-36201

Entity Registrant Name

IMMUNIC, INC.

Entity Central Index Key

0001280776

Entity Tax Identification Number

56-2358443

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1200 Avenue of the Americas

Entity Address, Address Line Two

Suite 200

Entity Address, City or Town

New York

Entity Address, State or Province

Entity Address, Country

Entity Address, Postal Zip Code

10036

City Area Code

(332)

Local Phone Number

255-9818

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.0001

Trading Symbol

IMUX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration